Spots Global Cancer Trial Database for irinotecan
Every month we try and update this database with for irinotecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer | NCT00048126 | Colorectal Canc... | Irinotecan capecitabine [X... | 18 Years - | Hoffmann-La Roche | |
| A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | NCT00993044 | Refractory Soli... | Irinotecan Vincristine Temozolomide Bevacizumab | 12 Months - 20 Years | Children's Hospital Los Angeles | |
| FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | NCT02485834 | Adenocarcinoma ... Gastric Adenoca... Gastric Cancer | FDG-PET surgery 5-FU capecitabine docetaxel Irinotecan 3D-CRT IMRT | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | NCT06139211 | Advanced Solid ... | JS015 Toripalimab Paclitaxel Irinotecan Capecitabine Oxaliplatin Bevacizumab Fluorouracil Leucovorin Gemcitabine Albumin-Bound P... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | NCT03295084 | Metastatic Colo... | Irinotecan Capecitabine | 18 Years - | Herlev Hospital | |
| Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer | NCT00160875 | Esophageal Canc... | Irinotecan hydr... Cisplatin | 18 Years - | University Health Network, Toronto | |
| Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | NCT00452634 | Small Cell Lung... | Irinotecan Cisplatin Simvastatin | 18 Years - | National Cancer Center, Korea | |
| A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer | NCT03522649 | Previously Trea... | Napabucasin Fluorouracil Leucovorin Irinotecan | 18 Years - | 1Globe Biomedical Co., Ltd. | |
| Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE) | NCT05646511 | Locally Advance... | SCRT CAPOX CAPOXIRI | 18 Years - | National Cancer Center Hospital East | |
| Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan | NCT00183859 | Adenocarcinoma Gastric Cancer | irinotecan | 18 Years - | University of Southern California | |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | NCT03222089 | Metastatic Colo... | Irinotecan Oxaliplatin Levoleucovorin 5-FU GM-CSF IL-2 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer | NCT02497157 | Metastatic Colo... | Oxaliplatin (L-... Irinotecan hydr... Continuous intr... Levofolinate ca... Bevacizumab (Bm... | 20 Years - 70 Years | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | |
| Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | NCT05381038 | Solid Tumor Gastrointestina... Breast Cancer | QPOP CURATE.AI Azacitidine + d... Azacitidine + p... Azacitidine + i... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | NCT01822613 | Esophageal Squa... | LJM716 BYL719 Paclitaxel Docetaxel Irinotecan | 18 Years - | Novartis | |
| A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma | NCT02539537 | Pancreatic Canc... Carcinoma | Gemcitabine Folinic Acid 5-Fluoro-uracil Oxaliplatin Irinotecan L-folinic | 18 Years - | UNICANCER | |
| A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT00642603 | Colorectal Canc... | capecitabine [X... capecitabine [X... bevacizumab [Av... oxaliplatin irinotecan | 18 Years - | Hoffmann-La Roche | |
| De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | NCT02842580 | Colorectal Neop... | 5 FLUOROURACYL acide folinique irinotecan Oxaliplatin capécitabine bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | NCT04361708 | Pancreatic Aden... Gastroesophagea... Adenocarcinoma | Oxaliplatin Docetaxel Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | University of Chicago | |
| Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | NCT00848783 | Gastric Cancer Gastric Adenoca... Esophageal Canc... | Irinotecan Cisplatin Surgery Floxuridine Capecitabine | 18 Years - | NYU Langone Health | |
| Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | NCT05330429 | Metastatic Colo... | Magrolimab Bevacizumab Irinotecan Fluorouracil Leucovorin | 18 Years - | Gilead Sciences | |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | NCT00718757 | Non-Hodgkins Ly... Hodgkin's Disea... Acute Lymphobla... | Dexamethasone Irinotecan Vincristine | - 21 Years | St. Jude Children's Research Hospital | |
| Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors | NCT02395068 | Solid Tumors | Nimotuzumab irinotecan | 18 Years - 70 Years | Biotech Pharmaceutical Co., Ltd. | |
| Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer | NCT00233623 | Metastatic Colo... | Iressa (Gefitin... Irinotecan 5Fluorouracil Leucovorin | 18 Years - | AstraZeneca | |
| Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | NCT00215501 | Solid Tumor | Capecitabine 5-Fluorouracil ... Irinotecan Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | NCT00871169 | Pancreatic Canc... | Irinotecan, oxa... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | NCT06401330 | Stage I Kidney ... Stage II Kidney... Stage III Kidne... Stage IV Kidney... | Bone Scan Carboplatin Computed Tomogr... Cyclophosphamid... Dactinomycin Doxorubicin Etoposide Irinotecan Magnetic Resona... Nephrectomy Patient Observa... Positron Emissi... Ultrasound Imag... Vincristine X-Ray Imaging | - 30 Years | Children's Oncology Group | |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | NCT00042939 | Pancreatic Canc... | cetuximab docetaxel irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | NCT00068692 | Rectal Mucinous... Rectal Signet R... Recurrent Recta... Stage IIA Recta... Stage IIB Recta... Stage IIC Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect... Stage IVA Recta... Stage IVB Recta... | Radiotherapy Fluorouracil Leucovorin Calc... Oxaliplatin Irinotecan | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | NCT00215501 | Solid Tumor | Capecitabine 5-Fluorouracil ... Irinotecan Cisplatin | 18 Years - | Dana-Farber Cancer Institute | |
| Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers | NCT02720601 | Biliary Tract C... | Irinotecan & Ca... | 18 Years - | New Mexico Cancer Care Alliance | |
| A Study of 5-FUci Versus CPT-11 Plus CDDP Versus S-1 Alone in Advanced Gastric Cancer | NCT00142350 | Gastric Cancer | continuous infu... combination of ... oral administra... | 20 Years - 75 Years | Japan Clinical Oncology Group | |
| Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | NCT02296203 | Metastatic Colo... | cetuximab irinotecan | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Biomarker Development for Response Prediction by DNA Mutational Analysis | NCT01855061 | Neoplasm Metast... | Biopsy Blood samples Pharmacokinetic... Midazolam clear... | 18 Years - | UMC Utrecht | |
| Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | NCT00522665 | Colorectal Canc... | Irinotecan Cetuximab RAD001 | 18 Years - | Hoosier Cancer Research Network | |
| Metastatic Gastric Cancer FFCD 03-07 | NCT00374036 | Stomach Cancer Neoplasm Metast... | ECC FOLFIRI | 18 Years - | University Hospital, Toulouse | |
| Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | NCT04358341 | Gastric Cancer | Irinotecan DOXOrubicin Lip... 5fluorouracil | 18 Years - 70 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT01075048 | Metastatic Colo... | Tivantinib Placebo Cetuximab Irinotecan | 18 Years - | Daiichi Sankyo | |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | NCT05999994 | Neoplasms Child Adolescent | Ramucirumab Cyclophosphamid... Vinorelbine Gemcitabine Docetaxel Abemaciclib Irinotecan Temozolomide | 1 Year - 39 Years | Eli Lilly and Company | |
| A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | NCT01131078 | Colorectal Canc... | Bevacizumab [Av... Capecitabine Irinotecan | 18 Years - | Hoffmann-La Roche | |
| Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | NCT02624726 | Metastatic Colo... | 5 Fluorouracil Leucovorin Irinotecan Aflibercept | 18 Years - | Hellenic Oncology Research Group | |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | NCT03665441 | Pancreatic Aden... | eryaspase Gemcitabine plu... Irinotecan plus... | 18 Years - | ERYtech Pharma | |
| Dendrobium Huoshanense Suppository in Rectal Cancer | NCT05079438 | Locally Advance... | Dendrobium Huos... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine | NCT00072852 | Breast Neoplasm... | Irinotecan | 18 Years - | Pfizer | |
| NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer | NCT00856375 | Colorectal Canc... | NKTR-102 irinotecan | 18 Years - | Nektar Therapeutics | |
| TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | NCT01060423 | Colorectal Canc... | Cetuximab Irinotecan Irinotecan elut... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | NCT05595889 | Small Cell Lung... Angiogenesis Chemotherapy Ef... | Surufatinib Irinotecan | 18 Years - 80 Years | Fujian Cancer Hospital | |
| Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors | NCT04337177 | Solid Tumors Neuroblastoma Rhabdomyosarcom... Ewing Sarcoma Hepatoblastoma Medulloblastoma | VAL-413 Temozolomide | 1 Year - 30 Years | Valent Technologies, LLC | |
| De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | NCT02842580 | Colorectal Neop... | 5 FLUOROURACYL acide folinique irinotecan Oxaliplatin capécitabine bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | NCT03430843 | Esophageal Squa... | Tislelizumab Paclitaxel Docetaxel Irinotecan | 18 Years - | BeiGene | |
| Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | NCT05610163 | Locally Advance... Stage II Rectal... Stage III Recta... | Capecitabine 5-fluorouracil Leucovorin calc... Irinotecan Oxaliplatin Long Course Che... Computed Tomogr... Magnetic Resona... Sigmoidoscopy biopsy | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | NCT02582970 | Colorectal Canc... | 5-Fluorouracil Bevacizumab Irinotecan Oxaliplatin | 18 Years - | Hoffmann-La Roche | |
| Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | NCT01560949 | Pancreatic Canc... | Oxaliplatin Irinotecan 5-FU Gemcitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | NCT01650428 | Rectal Cancer | Bevacizumab Irinotecan Oxaliplatin 5-Fluorouracil | 18 Years - 75 Years | University College, London | |
| Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer | NCT00569790 | Colorectal Canc... | S-1, Irinotecan... | 20 Years - | Taiho Pharmaceutical Co., Ltd. | |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | NCT05379595 | Advanced or Met... | Amivantamab Fluorouracil Leucovorin Oxaliplatin Irinotecan | 18 Years - | Janssen Research & Development, LLC | |
| Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | NCT02885753 | Colorectal Neop... | Oxaliplatin int... 5 FU bolus Folinic acid Oxaliplatin int... Panitumumab Bevacizumab 5 FU continuous Irinotecan | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | NCT03222089 | Metastatic Colo... | Irinotecan Oxaliplatin Levoleucovorin 5-FU GM-CSF IL-2 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | NCT00786669 | Solid Tumor | Bevacizumab Temozolomide Vincristine Irinotecan Cefixime | 1 Year - 30 Years | Children's Hospital Medical Center, Cincinnati | |
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma | NCT01383538 | Pancreatic Canc... Adenocarcinoma Pancreatic Neop... | FOLFIRINOX, IPI... | 18 Years - | University of California, San Francisco | |
| FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only | NCT01226719 | Colorectal Canc... | Panitumumab Oxaliplatin Irinotecan Leucovorin 5-Fluorouracil | 18 Years - | SCRI Development Innovations, LLC | |
| Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | NCT05722327 | Colon Cancer Colorectal Canc... | MRTX849 Irinotecan Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | NCT00193375 | Lung Cancer | Irinotecan Carboplatin Bevacizumab Radiation | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors | NCT00708773 | Advanced Cancer | Irinotecan | 18 Years - | University of Chicago | |
| Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | NCT00463073 | Malignant Gliom... | Cetuximab Bevacizumab Irinotecan | 18 Years - | Rigshospitalet, Denmark | |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | NCT00361244 | Colorectal Carc... | SU011248 Irinotecan Cetuximab | 18 Years - | Massachusetts General Hospital | |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | NCT01660711 | Pancreatic Aden... | 5 Fluorouracil Leucovorin Irinotecan Oxaliplatin | 18 Years - | NorthShore University HealthSystem | |
| Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | NCT00766220 | Colon Cancer Colorectal Canc... | SIR-spheres Age... Cetuximab Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | NCT04753879 | Metastatic Panc... | Nab-paclitaxel Gemcitabine Cisplatin Irinotecan Capecitabine Pembrolizumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer | NCT00036517 | Colorectal Neop... Diarrhea | PHY906 | 18 Years - 75 Years | PhytoCeutica | |
| The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer. | NCT05732129 | Homologous Reco... | Fluzoparib Irinotecan | 18 Years - 75 Years | Fudan University | |
| Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | NCT03053167 | ColoRectal Canc... | Irinotecan Raltitrexed | 18 Years - 75 Years | China Medical University, China | |
| Combination Therapy in Cancers With Mutations in DNA Repair Genes | NCT05694715 | Metastatic Soli... BRCA1 Mutation BRCA2 Mutation ATM Gene Mutati... PALB2 Gene Muta... | Niraparib Irinotecan | 18 Years - | University of California, San Francisco | |
| Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | NCT01523431 | Metastatic Colo... | Irinotecan Inje... 5-fluorouracil Leucovorin | 18 Years - | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer | NCT01693445 | Gastrointestina... | OIS (Oxaliplati... | 18 Years - | Hallym University Medical Center | |
| Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | NCT05319639 | Gastric Cancer ... | Oxaliplatin Levo-Leucovorin 5-fluorouracil Paclitaxel Irinotecan Tislelizumab | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer | NCT00081289 | Colorectal Canc... | Radiation Thera... Capecitabine 16... Capecitabine 12... Irinotecan Oxaliplatin Surgery Folinic Acid Fluorouracil Oxaliplatin | 18 Years - | Radiation Therapy Oncology Group | |
| Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | NCT03792269 | Colorectal Canc... Chemotherapy Ef... Chemotherapeuti... | Irinotecan Oxaliplatin Capecitabine | 18 Years - | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
